Moreover, BM stromal cell-derived exosomes induce resistance of RPMI8226 myeloma cells to bortezomib, which activates several survival-relevant pathways, including c-Jun N-terminal kinase (JNK), p38, p53, and protein kinase B (AKT) [21]. This evidence concerns the gene AKT1 and plasma cell myeloma.